SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is being discussed amid a cybersecurity-sector selloff, with traders citing sympathy pressure after Fortinets earnings reaction and broader weakness in software stocks rather than a company-specific catalyst. Some see the decline as a buying opportunity given ongoing security demand, while others argue CRWDs high valuation leaves it vulnerable to further pressure.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

A broad semiconductor and tech selloff, alongside worries about AI valuations and the durability of the sector rally, is weighing on CHPY. Traders are split between buying the dip on confidence in long-term chip demand and warning that further declines could erode the funds NAV and reduce distributions.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly results beat expectations and its full-year outlook rose, but softer Q4 organic-growth guidance and signs of slowing messaging growth drove a sharp selloff. Traders are debating whether the weaker near-term outlook outweighs the strong results, with some watching for support to hold and others wary of further post-earnings repricing.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisks share-price slump and competition from Eli Lilly dominate discussion, with traders criticizing management and questioning whether Novo can defend its position in the GLP-1 market. Ahead of Q3 results, bulls point to oral Wegovy demand and pipeline prospects, while skeptics doubt these can offset competitive and execution concerns.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,559,996,383.70523. The last known price of Dogecoin is 0.07552377 USD and is down -0.48 over the last 24 hours. It is currently trading on 1543 active market(s) with $337,365,256.17 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for weak, range-bound trading and repeated difficulty holding or reclaiming a key price threshold, alongside broader softness in crypto and meme coins. Traders are split between buying the dip and holding for a rebound, and bearish views citing continued declines and technical weakness.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto is drawing attention amid a cybersecurity-sector selloff after Fortinets weaker services-revenue outlook triggered sympathy selling in peers. Traders see the drop as either a buying opportunity in a still-growing security market or a valuation reset after a strong rally.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgans quarterly results missed expectations, with weaker fixed-income trading and securities losses offset by stronger lending income and loan growth. Traders are debating the stocks resilience despite the miss, while watching bank-sector conditions and interest-rate expectations.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims peptide opportunity is the dominant topic, after a temporary U.S. policy shift indicated regulators would not pursue enforcement against pharmacies compounding six peptides while they are reviewednot that the products received FDA approval. Traders are largely bullish on the potential new business, but many are frustrated by the stocks muted, volatile reaction and question whether Hims can turn the opportunity into revenue; some also expect earnings to be the next test.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in Japan, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBays stronger-than-expected third-quarter results and raised full-year outlook are drawing attention, with growth in marketplace volume and buyers boosting sentiment. Traders are weighing that performance against a more measured fourth-quarter outlook; recurring GameStop takeover speculation is also present but remains unconfirmed.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

RETIRE is drawing attention after a community-led campaign coincided with a sharp rally and increased trading activity, amplified by its on-chain 401(k) and early-retirement meme-coin narrative. Supporters emphasize the community and recurring DCA calls, while skeptics flag its speculative nature, volatility, and selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics (CGTX) delivered earnings and revenue surprises of +33.33% and -120.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%

Equity

The company reported that the U.S. Food and Drug Administration aligned with the company on several key aspects of the Phase 3 study, which is expected to begin in mid-2027.

Cognition Therapeutics (CGTX) to Release Earnings on Wednesday

Cognition Therapeutics (NASDAQ:CGTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-cognition-therapeutics-inc-stock...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the four analysts that are covering the firm, MarketBeat reports. One research...

Insider Buying: Cognition Therapeutics (NASDAQ:CGTX) CEO Acquires 9,175 Shares of Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were acquired at an...

John Brendan Doyle Purchases 10,000 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CFO John Brendan Doyle bought 10,000 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average cost of $1.13 per share, with a total value of $11,300.00. Following the completion of...

Lisa Ricciardi Acquires 9,175 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi acquired 9,175 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $1.10 per share, with a total value of $10,092.50. Following the...

Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans

Cognition Therapeutics (NASDAQ:CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage...

Q1 Earnings Forecast for CGTX Issued By HC Wainwright

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Cognition Therapeutics in a research report issued on Friday...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four research firms that are covering the stock, MarketBeat reports. One...

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Cognition Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The trial will evaluate once-daily 100 mg oral Zervimesine against a placebo in DLB patients experiencing hallucinations and delusions over a nine-month period.</li><li>The company plans to present additional Phase 2 data at the Alzheimer’s Association International Conference in July.</li><li>CGTX stock recorded its biggest single-day drop in nearly two years.</li></ul>Shares of Cognition Therapeutics (CGTX) tanked more than 33% on Wednesday, clocking their biggest single-day slide in nearly two years, as investors raised questions about the path forward for the company’s Phase 3 program targeting dementia with Lewy bodies (DLB) psychosis following a fresh regulatory update.<h2 class="st-heading-2">FDA Alignment On Phase 3 Trial</h2>The company reported that the U.S. Food and Drug Administration (FDA) provided favorable feedback on its planned Phase 3 program for Zervimesine in DLB psychosis. The agency aligned with the company on several key aspects of the pivotal study, which is expected to begin in mid-2027.The trial will evaluate once-daily 100 mg oral Zervimesine against a placebo in DLB patients experiencing hallucinations and delusions over a nine-month period.The Phase 3 trial is based on positive results from Cognition’s Phase 2 Shimmer study in patients with mild-to-moderate DLB, where the drug improved psychosis symptoms compared with placebo.A recent analysis showed the drug slowed the progression of hallucinations and delusions by 89%. The company plans to present additional Phase 2 data on these benefits at the Alzheimer’s Association International Conference (AAIC) in July.<h2 class="st-heading-2">What Are CGTX Traders Saying?</h2>While retail sentiment surrounding <a href="https://stocktwits.com/symbol/CGTX">CGTX</a> remained in the ‘extremely bullish’ territory over the past 24 hours, chatter focused on potential dilution to run the program.One user believes the “disappointment is the timeline” as the approved trial will not start for an entire year.<stembedurl>https://stocktwits.com/1rb/message/657295519</stembedurl>Another user said “pretty much zero catalyst the rest of the year,” while also expressing dilution concerns if the company fails to secure funding.<stembedurl>https://stocktwits.com/FitzCatalyst/message/657297638</stembedurl>As of March 31, 2026, the company had around $31.2 million in cash, cash equivalents, and restricted cash, along with $25.6 million in grants. The company believes its resources are sufficient to fund operations and capital spending through the second quarter of 2027.CGTX shares have declined more than 22% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/inmd-stock-gains-on-takeover-offer/cZKyQVJR7fZ">INMD Stock Heads For Best Day In Nearly Six Months – How Does The Latest Takeover Proposal Compare To Steel Partners’ Offer?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.6982
Prev Close	$0.7394
Open	$0.7216
Dividend Yield	0.00%
50-Day Moving Average	$0.9136
Beta	1.85
Avg. Volume	406,528.02
PE Ratio	-3.57

52-Week High	$1.83
52-Week Low	$0.5501
Market Capitalization	$66.39M
EPS (Annual)	-$0.3228
Price to Book	2.01
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGTX Fundamentals